Changes in Some Immunological and Biochemical Parameters in Patients with Chronic Hepatitis C with Increased Total Cardiovascular Risk and their Medical Correction


chronic hepatitis C
ribonucleic acid-based medicine
immunological parameters


Near 150 million people around the world suffer from chronic hepatitis C and 350 – 500 thousand die annually. Despite the large amount of studies devoted to the study of HCV-infection, the mechanisms of progression of chronic hepatitis C in patients with concomitant pathology are not quite determined today. The objective of this study was to examine the clinical-laboratory efficiency of treatment of chronic hepatitis C patients with increased total cardiovascular risk introducing medicine containing ribonucleic acid into the therapeutic regimen. The obtained results showed that the comprehensive application of antiviral therapy and ribonucleic acid-based medicine was accompanied by normalization of cytolytic syndrome, especially in patients with minimal or moderately manifested activity of hepatitis. In addition, a pronounced positive effect on rebalancing of the levels of biochemical parameters and cytokines was determined. For patients’ treatment it is appropriate to use ribonucleic acid-based medicine at a dose of 1.5 grams per day.


Anastasiy I.A. Place of ribavirin in complex treatment of chronic hepatitis C. Suchasni infektsii. 2010; 2: 117-123.

Golubovskaia O.A. Problematic issues of treatment of patients with hepatitis C [electronic resource] – Access:

Korchynskyy M.Ch. Use of the medicine Hepadyf® in patients with liver diseases of various etiologies. Suchasni infektsiii. 2010; 1: 97-104.

Nuclex: instructions for use. Approved 01.09. 2010 by the Order of the Ministry of Health of Ukraine No 752.

Unified clinical protocols of primary, secondary (specialized) medical care for adults and children. Viral hepatitis C. Approved 02.04.2014 by the Order of the Ministry of Health of Ukraine No 233.

Neshcheret O.P. Influence of the medicine Nuclex on the blood circulation and its adrenergic and cholinergic regulation. Fiziolohichnyi zhurnal. 2009; 6: 20-29.

Hural A.L., Mariyevskyy V.F., Serheyeva T.A. et al. Problems of epidemiology and prevention of hepatitis C in Ukraine. Infektsiini khvoroby. 2007; 3:23-30.

Porva Yu.I., Rybalko S.L., Tkachuk Z.Yu. et al. Antiviral action of RNA-based medicines on experimental infection of hepatitis C virus and surrogate virus – bovine viral diarrhea virus. Infektsiini khvoroby. 2010; 2:108-109.

Frolov V.M. Modern native medicine nucleinat – pharmacological activity and clinical application. Ukraiinskyi medychnyi almanakh. 2012; 15(4): 217-227.

McHutchison J.G. Understanding hepatitis C. Am. J. Manag. Care. 2004; 10(2): 21-29.

Tkachuk Z. Compound, composition and method for treatment of inflammatory and inflammatory-related disorders. United States Patent No US 6,737,271. May 18, 2004.

Tkachuk Z. Multiantivirus compound, composition and method of treatment of virus diseases. U.S. Patent Application. 2011; Bulletin 13, 046 – 240: 57.

Dykyi B., Tkachuk Z., Vaskul N. et al. Treatment of patients with hepatitis C using Nuclex. Sepsis. 2011; 4(1): 103.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Download data is not yet available.